Massachusetts Financial Services Co. MA Purchases 103,280 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Massachusetts Financial Services Co. MA raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 38.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 370,247 shares of the biopharmaceutical company’s stock after purchasing an additional 103,280 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.45% of Ultragenyx Pharmaceutical worth $15,217,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of RARE. UMB Bank n.a. grew its holdings in shares of Ultragenyx Pharmaceutical by 58.1% during the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 352 shares during the last quarter. US Bancorp DE increased its holdings in shares of Ultragenyx Pharmaceutical by 5.8% in the 1st quarter. US Bancorp DE now owns 7,143 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 390 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Ultragenyx Pharmaceutical by 2.1% in the second quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock worth $853,000 after purchasing an additional 434 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 8.7% during the first quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 486 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the first quarter valued at $28,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Trading Down 0.1 %

Shares of NASDAQ:RARE opened at $58.75 on Friday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $31.52 and a 12-month high of $60.37. The company has a market cap of $5.41 billion, a PE ratio of -7.32 and a beta of 0.56. The stock has a 50 day moving average of $52.03 and a 200 day moving average of $46.49.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The firm had revenue of $147.03 million during the quarter, compared to analysts’ expectations of $123.20 million. During the same period in the prior year, the company posted ($2.25) earnings per share. The company’s revenue for the quarter was up 35.7% compared to the same quarter last year. Equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the transaction, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 40,675 shares of company stock valued at $2,149,446 over the last ninety days. 5.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on RARE. Wedbush boosted their target price on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. The Goldman Sachs Group raised their target price on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Stifel Nicolaus boosted their target price on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a research note on Friday, May 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a report on Monday, September 16th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $87.43.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.